The European Commission said on Thursday it had signed a contract with U.S. drugmaker Gilead for the supply of up to 500,000 treatment courses for remdesivir, sharply increasing the supply of the COVID19 treatment in Europe.
BRUSSELS: The European Commission said on Thursday it had signed a contract with U.S. drugmaker Gilead for the supply of up to 500,000 treatment courses for remdesivir, sharply increasing the supply of the COVID-19 treatment in Europe.
The Commission, which has overseen joint purchases of vaccines in the European Union, said there were 37 signatories to the agreement, including all EU countries, six Balkan candidate and potential EU members, Britain and the other European Economic Area countries Iceland, Liechtenstein and Norway.
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor
Read all the Latest News and Breaking News here
Comments
0 comment